drugset / Trial / NCT05750589
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-01-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX-101 | Unknown | — | — |
| Comparator | Providone-Iodine | Unknown | — | — |